



**KTH Biotechnology**

# **Very high cell density perfusion of CHO cells in disposable bioreactor, challenge or reality**

Véronique Chotteau  
Cell Technology group (CETEG)  
KTH, School of Biotechnology, Div. Bioprocess

## Perfusion in industry for animal cell

- Majority of fed-batch processes world-wise
- Perfusion used 'traditionally'
  - for unstable proteins
  - in companies or lab's with 'culture' perfusion, i.e. where knowledge, competence and PEOPLE are present
- Perfusion
  - more technically challenging → higher risk of failure, higher risk of contamination
  - smaller cultivation vessel
  - less process development
  - constant cellular environment is beneficial for cell metabolism and product quality
- Perfusion equipment robust and disposable
  - robust equipment → higher risk of failure
  - disposable equipment → higher risk of contamination

## Three systems studied at CETEG (KTH)


### Collaborations

- WAVE Bioreactor™ equipped with ATF GE Healthcare (Sweden, USA)
- WAVE Bioreactor™ equipped with TFF GE Healthcare (Sweden, USA)
- CellTank™ CerCell (Denmark), Belach (Sweden)

## WAVE Bioreactor™ in perfusion with ATF or TFF

- Goal

- Evaluation of disposable WAVE Bioreactor™ in perfusion mode
- Evaluation of two types of cell separation based on hollow fiber filtration:
  - Alternating Tangential Flow filtration
  - Tangential flow filtration
- Evaluation of the limits of the system



WAVE Bioreactor™

source: <http://www.gelifesciences.com>

- Strategy

- Cell line #1 = IgG producing Chinese Hamster Ovary cells
- Study of perfusion → learning phase and study of the equipment
- Study of perfusion → study of the limits of the system
- Evaluation for application of IgG production and comparison with fed-batch
- Evaluation for application of cryopreservation / cell banking

## CellTank™ in perfusion mode

- Goal
  - Evaluation of disposable CellTank™ in perfusion mode (CerCell, Denmark)
  - Evaluation of the system
- Strategy
  - Cell line #2 = IgG producing Chinese Hamster Ovary cells
  - Study of perfusion → trouble shooting / learning phase and study of the equipment
  - Study of perfusion →
    - Evaluation of the system at very high cell density
    - Evaluation of effect of temperature decrease







# Introduction and System set-up


# Perfusion devices connected to WAVE Bioreactor™

**ATF** (*REFINE Technology*)  
**A**lternating  
**T**angential  
**F**low  
*with*  
*ReadyToProcess™ filter*  
*GE Healthcare*



**TFF**  
**T**angential  
**F**low  
**F**iltration  
*with*  
*ReadyToProcess™ filter*  
*GE Healthcare*



# ATF & WAVE Bioreactor™




# TFF & WAVE Bioreactor™



**WAVE™ Cellbag 10 L**

**Hollow fiber filter**

**ATF-2**





**TFF**

**Pump  
Watson  
Marlow  
620S**





# CellTank (CerCell)

CellTank  
(CerCell)  
photo



# CellTank 2202 system at CETEG



## Experimental set-up TTF and ATF runs with Wave Bioreactor™

Cell line	mAb producing DHFR <sup>r</sup> CHO #1					
Bioreactor	10 L WAVE Cellbag™ with two dip tubes (GE Healthcare)					
Working volume	4 L					
Cell separation device	ATF-2 (Refine Technology) & ReadyToProcess™ filter					
	TFF ReadyToProcess™ filter via Watson Marlow 620S pump					
Hollow fiber filters (HF)	ReadyToProcess™ filter polysulfone RTPCFP-2-E-4X2MS (GE Healthcare)					
	pore size	0.2 μm	lumen	1 mm	filter area	850 cm <sup>2</sup>
Recirculation flow rate*	(0.7 or) 1 L/min → shear rate 3400 s <sup>-1</sup>					
Cell density specific perfusion rate	0.05 Reactor Volume/(day x 10 <sup>6</sup> cells/mL)					
pH	7 control by adding 0.5 M Na <sub>2</sub> CO <sub>3</sub> or pulsing CO <sub>2</sub> into headspace					
Temperature	37°C					
DO	35 % control by varying the agitation, O <sub>2</sub> addition into headspace (20-100%)					
Agitation rate / rocking angle	ATF 20-26 rpm / 6-7°					
	TFF 20-27 rpm / 6-8°					
Cultivation medium	animal-component free IS CHO CD XP medium with hydrolysate (Irvine Scientific) + 3 % of IS-CHO Feed-CD XP (Irvine Scientific)					
Supplementations of glucose and glutamine	according to cell consumption					
Addition of Antifoam C (SAFC)	up to 50 ppm concentration (boost addition or by continuous pumping)					
Analyses by Nova Bioprofile FLEX	cell density, viability, cell diameter, pH, pCO <sub>2</sub> , osmolality, concentrations of glucose, glutamine, lactate and ammonia					
Analysis of mAb concentration	protein A HPLC					

\* or pressure rising flow (ATF) and exhaust flow (ATF)


## Experimental set-up CellTank™

Cell line	mAb producing DHFR <sup>-</sup> CHO (DP12)
Bioreactor and cell separation device	CellTank™ (CerCell) with matrix (~12 grams non-woven polyester matrix) @ ~ 3.6 m <sup>2</sup> matrix surface
Working volume	150 mL
Recirculation flow rate*	1 & 1.6 L/min
Cell density specific perfusion rate	≥ 0.05 nL/cell/day (or 1 Reactor Volume/day for 20 x 10 <sup>6</sup> /mL)
pH	7 & 7.1 control by adding 0.5 M Na <sub>2</sub> CO <sub>3</sub> or pulsing CO <sub>2</sub> into headspace
Temperature	37°C & 29 to 32°C
DO	40 & 45 % control by O <sub>2</sub> sparging
Cultivation medium	animal-component free IS CHO CD XP medium with hydrolysate (Irvine Scientific) + 3 % of IS-CHO Feed-CD XP (Irvine Scientific)
Supplementations of glucose and glutamine	according to cell consumption
Addition of Antifoam C (SAFC)	/
Analyses by Nova Bioprofile FLEX	cell density, viability, cell diameter, pH, pCO <sub>2</sub> , osmolality, concentrations of glucose, glutamine, lactate and ammonia
Analysis of mAb concentration	protein A HPLC

## Results


# Perfusion using ATF or TFF in Wave Bioreactor™

## Continuation of run using TFF at very high cell density




- Cell density stabilized at  $100 \times 10^6$  and  $120 \times 10^6$  cells/mL by daily cell bleeds during > 2 weeks
- Cell densities  $\geq 200 \times 10^6$  cells/mL (2 days)  $\rightarrow$  Max cell density =  $214 \times 10^6$  cells/mL
- Cell density limit due to limitations of membrane capacity for the encountered high viscosity (pressure = 1 bar), oxygenation and CO<sub>2</sub> level (31 kPa)

# Perfusion using ATF or TFF at very high cell densities



- Max cell density =  $132 \times 10^6$  cells/mL using ATF
- After maximum reached → cell density maintained at  $\approx 100 \times 10^6$  cells/mL using ATF
- Cell density limit due to pressure limitation to push highly viscous fluid using non-pressurisable disposable bioreactor

# Total accumulated antibody production in the harvest, the cell bleed, the bioreactor and cell density using TFF




ZOOM

- Observation of partial IgG retention by the hollow fiber filter
- Calculation exercise in this study run
  - 17 days at  $\approx 20\text{-}30 \times 10^6$  cells/mL  $\rightarrow \approx 7$  g
  - 47 days at  $\approx 25 \times 10^6$  cells/mL and  $\approx 110 \times 10^6$  cells/mL  $\rightarrow \approx 96$  g



Total accumulated antibody production in the harvest, the cell bleed, the bioreactor and cell density using **TFF** or **ATF** after 17 days at  $\approx 25 \times 10^6$  cells/mL



**ATF**


**TFF**

- |   |              |              |
|---|--------------|--------------|
| • Partial retention of IgG by hollow fiber filter                 | yes          | <b>yes</b>   |
| • Cell specific productivity (pg/cell/day)                        | <b>10-15</b> | <b>10-15</b> |
| • Total accumulated production                                    | <b>12</b>    | <b>12</b>    |
| • Accumulated production in harvest (g)                           | <b>9</b>     | <b>7</b>     |
| • Total removal of mAb in cell bleeds/total production (w/w in %) | <b>19</b>    | <b>30</b>    |
| • Yield (production in harvest/total production) (w/w in %)       | <b>75</b>    | <b>55</b>    |
| • Residual mAb mass in bioreactor/total production (w/w in %)     | <b>6</b>     | <b>15</b>    |

# Results

## Perfusion using CellTank™

## Cell density and perfusion rate in CellTank runs (BOL#1, BOL#2)





BOL#1: Fast growth after day 14 (after trouble shooting (1<sup>st</sup> run)) → up to **200 x 10<sup>6</sup>/mL**


BOL#2: Cell density kept ≈ **130 x 10<sup>6</sup>/mL** at perfusion rate of 8-10 RV/day for over 10 days

Temperature lowered from 37°C to 32°C/31°C/30°C/29°C on day 16 → cell growth arrest

# IgG production in CellTank™ runs



- Product accumulated with time and increasing cell density (after day 14 for BOL#1)
- Cell specific productivity in perfusion mode comparable to shake flask productivity except at 30°C where it was  $\approx 40\%$  higher
- No retention of IgG in the polymer matrix.




## Results

# Fed-batch versus perfusion using ATF or TFF


## Comparison with fed-batch process

### Experimental set-up

- Initial → final volume = 2 L → 4 L
- Same set-points of DO, pH
- Temperature → 37°C (run FB#11) and 35.5°C from day 7 (run FB#16)
- Base medium = IS CHO CD XP medium with hydrolysate (Irvine Scientific)
- Feed medium = base medium + feed concentrate Efficient Feed A & B (InVitrogen)



# Production in perfusion or fed-batch 4 L WAVE Bioreactor™




	Fed-batch	Perfusion (ATF or TFF) with cell density at $\approx 25 \times 10^6$ cells/mL	Perfusion (calculated from analyses in run TFF#10) with cell density at $\approx 100 \times 10^6$ cells/mL
mAb production after 17 days run	$\approx 2$ g	$\approx 7$ to $9$ g	$\approx 34$ g (Rm: $\approx 22$ g/week produced at $10^8$ cells/mL)

## Results

# Cryopreservation from very high cell density perfusion



## Cryopreservation study: set-ups




After cryopreservation (N2 tank)

- Cell thaw in shake flasks at  $10^6$  cells/mL
- Study of cell revival and mAb production


*Rm: freezing single experiment*

## Cell thaw after cryopreservation from high cell density culture



- Cryopreservation from  $100 \times 10^6$  cells/mL in vials of  $100$  or  $50 \times 10^6$  cells/mL  
 → excellent cell resuscitation

# Cryopreservation: Production test in shake flasks 2 weeks after thaw




- Normal mAb production 2 weeks after thaw

## Cells at very high cell density

# Cell diameter at very high cell density

## 1. TFF perfusion run in Wave Bioreactor™




Smaller cell diameter when cell density >  $131 \times 10^6$  cells/mL



2. Perfusion run in CellTank™ → cell diameter smaller when cell density  $\geq 144 \times 10^6$  cells/mL (Fogale cell density probe - multi-frequency signal)

## Distance between cells for different cell diameters


Calculation with hypothesis that cells are perfect incompressible spheres



# Pressures during TTF perfusion



## Viscosity very well correlated with cell density



$$\text{Viscosity} = 0.01 (1 + 2.5 \Phi + 14.1 \Phi^2)$$

$\Phi$  = volume fraction of cells in the mixture

Calculation for cell diameter 17  $\mu\text{m}$  of viscosity of slurry according to Thomas D. G. 1965 J. Colloid Science 20:267

- ➔ Increased viscosity due to increased cell density
- ➔ Increased pressure due to increased viscosity in a constricted filter section
- ➔ Calculation of filter fiber numbers (or filter section) can be done given target cell density, allowed inlet pressure





# Conclusions

## Conclusions – Cell density

- Very high cell density of  $100 \times 10^6$  cells/mL stably maintained in growing phase and at high viability by cell bleeds in a perfused WAVE Bioreactor™ using TFF or ATF cell separations
- Very high cell density of  $200 \times 10^6$  cells/mL achieved in CellTank™
- Very high cell density of  $130 \times 10^6$  cells/mL during 11 days with lower temperature in CellTank
- With present settings → maximal cell density =  $214 \times 10^6$  cells/mL with TFF  
→ maximal cell density =  $132 \times 10^6$  cells/mL with ATF
- TFF → cell density limited by membrane capacity (for the encountered high viscosity), oxygenation and CO<sub>2</sub> level
- ATF → cell density limited by insufficient pressure to push highly viscous fluid when using non-pressurisable disposable bioreactor
- ➔ TFF and CellTank™ allow reaching higher cell densities than ATF with present settings
- First time, CHO cell density  $200 \times 10^6$  cells/mL in a wave-agitated bioreactor
- First time, CHO cell density  $200 \times 10^6$  cells/mL in CellTank

## Conclusions – Cell density limit?

- **Upper limit of cell density for suspension**
  - depends of cell diameter
  - calculated theoretically for perfect spheres
  - for CHO cells (diameter 16  $\mu\text{m}$ )  $\rightarrow$  250 x 10<sup>6</sup> cells/mL
  - smaller limit than tissue cells or adherent cells in absence of contact inhibition
- **Applicable limit of cell density for suspension**
  - depends of cell diameter
  - depends of equipment
  - impact of cell shrinking?
    - perhaps recommended to avoid shrinking
    - limit of 130 x 10<sup>6</sup> cells/mL for CHO cells
    - theoretical smallest distance between cells with unchanged diameter = 2  $\mu\text{m}$

## Conclusions – mAb production

- No retention of mAb in CellTank™ matrix using cell line #2
- Retention using cell line #1 in hollow fibre filter: Higher retentions of mAb by hollow fibre filter using TFF than ATF using
- In perfusion, major effect of this retention = loss of mAb in the cell bleeds
- ➔ CellTank™ the most favourable for production according to this study
- ➔ ATF more favourable for production at stable cell density maintained by cell bleeds
- Potential production per bioreactor volume by perfusion much larger than fed-batch

## Conclusions – Operation

- Recommended to apply **cell specific perfusion rate**
- No cell sample today in **CellTank™** (under development)
- **Short residence time**  $\approx$  20-30 sec for **TFF** and **ATF**
- **Short 'residence time'**  $\approx$  6-9 sec for **CellTank™**
- **Shear rate of 3400 s<sup>-1</sup> well tolerated** for **TFF** and **ATF**
- **TFF ReadyToProcess** disposable, **easy** to **put in place** and easy to **put a new hollow fiber filter** during cultivation  $\rightarrow$  **easier** operation than ATF (autoclavable)
- Operation using **CellTank™** **easy** and **handy** with robust integrated perfusion device
- Operation during 24 and 27 days could have been continued longer
- **Absence of sparging** in **Wave Bioreactor™** and in **CellTank™** in small scale  $\rightarrow$  **ADVANTAGEOUS**
- The use of a **single-use** bioreactor equipped with **robust cell separation** device offers a solution alleviating technical and sterility challenges occurring in perfusion processes

## Conclusions – Hollow fiber operation

- Present study give mathematical tools to select / design hollow fibers
  - lumen size and / or number of fibers → important for high cell density
  - recommendation of larger lumen or larger number of fibers
  - recommended to use larger number of fibers than 50 fibers (present study) using ATF for cell density  $\geq 100 - 120 \times 10^6$  cells/mL in disposable bioreactor
  - filter area → impact on fouling

## Perspectives - Applications

High or very high cell densities of CHO cells, i.e. 50 to 130 x 10<sup>6</sup> cells/mL, are applicable for

	Wave Bioreactor™ & TFF or ATF	CellTank™ (1)
Seed bioreactor	X	
Production bioreactor <ul style="list-style-type: none"> <li>– instable protein</li> <li>– non mAb (where fed-batch platform not straight applicable)</li> <li>– small company lacking fed-batch platform</li> </ul>	X	X
Rapid, non optimized production of protein (e.g. explorative research) <ul style="list-style-type: none"> <li>– compensation of low titer by very high cell density</li> </ul>	X	X
Cell expansion for cell banking <ul style="list-style-type: none"> <li>– cryopreservation from culture at 100 x 10<sup>6</sup> cells/mL</li> <li>– good cell resuscitation and normal mAb production</li> <li>– allows significant time cuts in cell banking and cell expansion</li> </ul>	X	

(1) Cell detachment is in development

## Acknowledgements



ROYAL INSTITUTE  
OF TECHNOLOGY

### ***Co-authors***

Marie-Francoise  
Clincke  
Carin Mölleryd  
Puneeth Samani  
Ye Zhang

### ***Thanks to***

Atefeh Shokri  
Jan Kinnander  
Alexis Braun

GE Healthcare



Sweden/USA

### ***Co-authors***

Eva Lindskog  
Kieron Walsh  
Eric Fäldt

### ***Thanks to***

Christian  
Kaisermayer  
Craig  
Robinson



### ***Co-authors***

Per Stobbe



### ***Co-authors***

Christian  
Orrego



Swedish  
Governmental  
Agency for  
Innovation  
Systems